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Abstract
Background: Cluster randomized trials are an increasingly important methodological tool in
health research. In cluster randomized trials, intact social units or groups of individuals, such as
medical practices, schools, or entire communities – rather than individual themselves – are
randomly allocated to intervention or control conditions, while outcomes are then observed on
individual cluster members. The substantial methodological differences between cluster
randomized trials and conventional randomized trials pose serious challenges to the current
conceptual framework for research ethics. The ethical implications of randomizing groups rather
than individuals are not addressed in current research ethics guidelines, nor have they even been
thoroughly explored. The main objectives of this research are to: (1) identify ethical issues arising
in cluster trials and learn how they are currently being addressed; (2) understand how ethics
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Trials 2009, 10:61 http://www.trialsjournal.com/content/10/1/61reviews of cluster trials are carried out in different countries (Canada, the USA and the UK); (3)
elicit the views and experiences of trial participants and cluster representatives; (4) develop well-
grounded guidelines for the ethical conduct and review of cluster trials by conducting an extensive
ethical analysis and organizing a consensus process; (5) disseminate the guidelines to researchers,
research ethics boards (REBs), journal editors, and research funders.
Methods: We will use a mixed-methods (qualitative and quantitative) approach incorporating both
empirical and conceptual work. Empirical work will include a systematic review of a random sample
of published trials, a survey and in-depth interviews with trialists, a survey of REBs, and in-depth
interviews and focus group discussions with trial participants and gatekeepers. The empirical work
will inform the concurrent ethical analysis which will lead to a guidance document laying out
principles, policy options, and rationale for proposed guidelines. An Expert Panel of researchers,
ethicists, health lawyers, consumer advocates, REB members, and representatives from low-middle
income countries will be appointed. A consensus conference will be convened and draft guidelines
will be generated by the Panel; an e-consultation phase will then be launched to invite comments
from the broader community of researchers, policy-makers, and the public before a final set of
guidelines is generated by the Panel and widely disseminated by the research team.
Background
Cluster randomized trials
In recent years, there has been a growing interest in gener-
ating dependable evidence about the effectiveness of
health policies, programs and practices, using rand-
omized designs. In some studies, randomization at the
individual (patient) level may not be feasible because the
intervention is designed to be implemented at the group
level or because the hypothesized mechanism of action of
the intervention operates at the group level. In health serv-
ices implementation research [1] for example, the inter-
vention may be administered to the health professional or
may involve changes to the health care organization; and
in trials of infectious disease interventions, a vaccine may
be administered at the individual level but its effects
observed among those in the wider community as a con-
sequence of herd immunity. Randomization at the indi-
vidual level may also be undesirable for methodological
reasons such as the need to avoid contamination (for
example, in trials of behavioural interventions) when
individuals in close proximity are randomized to compet-
ing interventions. Finally, randomizing individuals may
complicate the trial organization and implementation, for
example, in developing nation settings where special
equipment or personnel are required or permission from
political authorities must be obtained to conduct the trial.
The cluster randomized design [2] has thus become an
increasingly important methodological tool in health and
health services research: in cluster randomized trials (also
known as group randomized or place randomized trials),
intact social units or clusters of individuals, such as med-
ical practices, communities, schools or villages are rand-
omized to intervention or control conditions. The
interventions may be delivered to the entire randomized
group as a unit, or to individuals within each group, but
all members of a group receive the same intervention; out-
comes are then observed on individual cluster members
(or subsamples of members) to evaluate the effect of the
experimental intervention. Note that, although outcomes
are observed on individuals, they may be aggregated at the
cluster-level, for example, percentage of X-ray requests by
physicians.
Ethical challenges in cluster randomized trials
The substantial methodological differences between clus-
ter randomized trials and conventional randomized trials
pose serious challenges to the current conceptual frame-
work for research ethics. Contemporary research ethics is
largely structured around the protection of the autonomy
and welfare interests of individual research subjects. Ethi-
cal principles governing the conduct of clinical research
are laid out in the Belmont Report [3]. The ethical princi-
ple of respect for persons means that choices of autono-
mous individuals ought to be taken seriously and that
persons who cannot responsibly choose for themselves
are entitled to protection. This principle is the source of
the moral rules requiring informed consent from research
subjects and protection of confidential health informa-
tion. The ethical principle of beneficence means that
researchers have an obligation to protect subjects from
avoidable harm and, where possible, to promote their
welfare interests. It is the source of a variety of moral rules
that guide the ethical analysis of study benefits and harms
[4]. The ethical principle of justice means that study sub-
jects ought to be treated fairly. It grounds requirements
that the vulnerable, such as children or incapable adults,
not be included as a population of mere convenience.
Recently, a novel ethical principle of respect for commu-
nities has been proposed [5]. It requires that investigators
have an obligation to respect communal values, protectPage 2 of 10
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abide by the decisions of legitimate communal authori-
ties.
The ethical implications of randomizing groups rather
than individuals have as yet not been thoroughly explored
[6-11]. This is illustrated by the ethical issues arising from
three different cluster randomized trials: In the Commu-
nity Intervention Trial for Smoking Cessation (COMMIT)
[12], twenty-two cities in the USA and Canada were rand-
omized to either a community-level antismoking inter-
vention delivered through mass media, health care
professionals and worksites, or to a no-intervention con-
trol. Baseline data were collected from a random sample
of citizens using a telephone survey, and a sample of
smokers identified and followed with annual telephone
surveys to ascertain smoking cessation status. The investi-
gators interacted with the community by forming a board
of community representatives. Individual respondents
were not aware that they were involved in a trial, although
they provided verbal consent to complete the telephone
surveys. Questions raised by this study include: Is consent
required from the communities involved? [8] If so, from
whom? Is the municipal government empowered to make
these decisions? [13] What criteria ought community deci-
sion-makers use? [10] When the intervention is targeted at
the entire community, it may be impossible to obtain
individual informed consent from all citizens – is this eth-
ically legitimate, or does an inability to consent to or opt
out of a community-level intervention violate the rights of
individual citizens? [13]
Analogous questions arise in quality improvement inter-
ventions where the intervention may be targeted at health
professionals but affect patient care. For example, in a
cluster randomized trial to improve adherence to guide-
lines for hypertension drug prescribing, physicians and
nurse practitioners were randomized to receive either gen-
eral guideline education or education plus patient-specific
reminders about hypertension [14]. Outcomes included
overall compliance with guidelines and adequacy of
patients' blood pressure control as ascertained by review
of patients' medical records. The requirement for
informed consent for both practitioners and individual
subjects was waived by the Research Ethics Board (REB).
Questions raised by this study include: Who are the
research subjects: health professionals, patients, or both?
Should consent be required from the participating health
professionals [9] or is there a professional obligation for
health professionals to participate in quality improve-
ment research that obviates the need for their informed
consent? If the study is using routinely-collected data with
identifying information removed, is patient consent
required? How are we to understand this study with
respect to the analysis of benefits and harms? [13]
A third, very different study randomized villages in Nepal
to provide nutritional supplements to women of child-
bearing age [15]. Villages were randomized to one of four
study arms: vitamin A supplements, -carotene supple-
ments, both supplements, or placebo. The outcome of
interest was mortality associated with pregnancy and
childbirth. Community leaders agreed to randomization
of communities, while individual women gave verbal
consent to receive the supplements and provide data. A
sample of women who became pregnant underwent fur-
ther investigations, including blood sampling. Mortality
and other variables were collected prospectively by study
workers. Further information regarding fatalities was
obtained from interviews with the families of any subjects
who died. While this study shares many of the issues
raised in the first example, additional questions include:
Do investigators bear any special obligations to subjects
because of the developing nation setting [5]? Is there an
obligation to offer ancillary benefits to the control arm or
to all study arms (e.g., additional health care unrelated to
the study question) [11]?
Inadequacy of Current Research Ethics Guidelines
Given the uncertainty in the literature as to how to address
the ethical problems presented by cluster randomized tri-
als, it is not surprising that current research ethics guide-
lines do not address these issues. Relevant international
and national guidelines include the World Medical Asso-
ciation Declaration of Helsinki [16], the Council of Interna-
tional Organizations of Medical Sciences (CIOMS)
International Ethical Guidelines for Biomedical Research
Involving Human Subjects [17], the International Confer-
ence of Harmonization Guideline for Good Clinical Practice
[18], CIOMS 1991 International Guidelines for Ethical
Review of Epidemiological Studies [19], Canadian Tri-Council
Policy Statement [20], United Kingdom Medical Research
Council Guidelines for Good Clinical Practice in Clinical Trials
[21], and US federal regulations [22]. These guiding doc-
uments were designed to protect the welfare and liberty
interests of individual research subjects, but little guid-
ance is provided with respect to community-based
research, let alone cluster randomized trials. The sole
exception is the UK Medical Research Council document
(Cluster Randomized Trials: Methodological and Ethical Con-
siderations) [8]; however, this document does not address
the broad scope of ethical issues identified above, and its
applicability to the regulatory environments of other
countries is uncertain.
Researchers need direction on these ethical challenges in
order to guide the ethically appropriate design and con-
duct of cluster randomized trials. REBs may be unfamiliar
with this increasingly important study methodology. In
the absence of formal guidelines for cluster randomized
trials, REBs may fail to consider all of the relevant ethicalPage 3 of 10
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quate subject protection. Variable interpretation of ethical
requirements for cluster randomized trials may lead to
problems initiating multi-jurisdictional cluster rand-
omized trials, and to unequal treatment of subjects in dif-
ferent jurisdictions. For example, Chaney et al. [23]
reported on a series of health services implementation
research studies involving primary care centres in the USA
in which a combined total of more than 100 ethics review
applications, amendments, and renewals were submitted
at 17 research sites. Substantial variation in process and
outcomes among sites was reported, with 35% of sites
considering the research as exempt from review, 41%
granting expedited review, and 18% requiring full review;
approximately half of the REBs had ethical concerns
necessitating changes to consent documents, and the
number of days from submission to approval varied
widely among sites, ranging from 3 to 82 days. Dziak et al.
[24] reported on the ethics review process in a health serv-
ices research study involving 15 primary care sites; REBs
varied in the types of review required, and the number of
days from submission to approval ranged from 5 to 172
days. According to the authors, variability in requirements
for informed consent resulted in significantly different
response rates among sites and affected sample generaliz-
ability.
Study objectives
The overarching goals of this study are to promote high
ethical standards in cluster randomized trials and to pro-
mote uniformity in the ethics review of cluster rand-
omized trials through the development of explicit
guidelines. Specific objectives are to:
1. Identify challenges arising in the ethical conduct of
cluster randomized trials through examination of pub-
lished trial reports and elicitation of the views and experi-
ences of researchers (cluster randomization trialists);
2. Identify challenges arising in the ethical review of clus-
ter randomized trials through elicitation of the views and
experiences of researchers and REBs;
3. Elicit the views of research participants (patients, mem-
bers of the public, and gatekeepers or cluster level deci-
sion-makers) regarding ethical issues in cluster
randomized trials;
4. Develop well-grounded guidelines for the ethical con-
duct and review of cluster randomized trials by conduct-
ing an extensive ethical analysis and organizing a
consensus process;
5. Disseminate the guidelines to researchers, REBs, journal
editors and funders of research.
Work Leading up to this Study
In preparation for this research study, we conducted inter-
views with 22 key informants, including ethicists, statisti-
cians, and trialists experienced in cluster randomized
trials. The interviews were conducted using a semi-struc-
tured interview guide and addressed informants' experi-
ences with the ethics review process and ethical challenges
arising in cluster randomized trials. Interviews were con-
ducted by telephone and were audio-taped with the par-
ticipants' consent. Audio-tapes were transcribed verbatim,
verified by the interviewer, and imported into a qualita-
tive software package NVivo 8 (QSR, Inc. Victoria, Aus-
tralia) to facilitate thematic coding, evaluation and
analysis. This necessary preliminary work was carried out
to generate an initial framework of ethical issues arising in
cluster randomized trials, as seen from a variety of
research perspectives. The framework will continue to be
updated as the study progresses. Results from the key
informant interviews and qualitative analysis will be pub-
lished elsewhere.
Methods
Our study design utilizes a mixed-methods (qualitative
and quantitative) approach incorporating both empirical
and conceptual work. An outline of the study design is
presented in Figure 1.
Overview
Empirical work will include: a systematic review of a ran-
dom sample of published cluster randomized trials; a sur-
vey of cluster randomization trialists supplemented by in-
depth interviews; a survey of REBs; and focus group dis-
cussions and in-depth interviews with trial participants
and gatekeepers (cluster level decision-makers). The
empirical work will inform the concurrent conceptual
(ethical) analysis which will lead to a guidance document
laying out principles, policy options, and rationale for rec-
ommendations. An Expert Panel will be appointed and a
consensus conference will be convened. Draft guidelines
will be generated by the Panel and an e-consultation
phase will be launched. Guidelines will then be revised by
the Panel and widely disseminated by the research team.
Empirical work
Systematic Review of Published Cluster Randomized Trials
We will conduct a systematic review of a random sample
of 300 cluster randomized trials in health research pub-
lished between 2000 and 2008. A sampling frame of
reports of cluster randomized trials will be identified in
Medline by implementing an electronic search strategy
(with sensitivity 90.1%) that has been developed and val-
idated by our team [Taljaard M, McGowan J, Grimshaw J
et al. 2009. Electronic search strategies for identifying cluster
randomized trials in Medline. Unpublished Manuscript].
We will select a random sample of 300 eligible trials fromPage 4 of 10
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Outline of the research planFigur 1
Outline of the research plan.
 
 
Trials 2009, 10:61 http://www.trialsjournal.com/content/10/1/61the identified reports using computer-generated random
numbers. Specific inclusion and exclusion criteria for tri-
als are summarized in Appendix 1.
Using data abstraction forms that have been developed
and extensively pilot tested by the research team, we will
abstract data on characteristics of the study design, inter-
ventions, and outcomes collected; details of informed
consent procedures, if any, at individual and cluster level;
and details of the ethics review process. Initial samples of
20 trials will be used for reviewer calibration. Thereafter,
two reviewers will independently abstract data from each
trial report. Agreement between reviewers will be assessed
using kappa statistics, with differences resolved by discus-
sion. Frequency distributions will be generated to com-
pare the prevalence of identified ethical issues such as
informed consent procedures among study disciplines,
types of randomization units, types of interventions, over
time, and other descriptors. The sample size of 300 trials
is sufficient to give a 95% two-sided confidence interval
extending ± 5.7% from an observed proportion of 50%.
Results from the systematic review will be used to inform
the ethical analysis and to help develop survey question-
naires and interview guides for further empirical work.
Survey and In-depth Interviews with Cluster Randomization Trialists
As all ethical issues of interest are unlikely to be fully
reported in published articles, the systematic review will
be supplemented by a mail survey of corresponding
authors of the included trial reports. The survey will con-
sist primarily of closed-ended questions and will elicit tri-
alists' views on ethical issues in cluster randomized trials
in general, and gather further information on the pub-
lished trial included in the systematic review, including
consent procedures used at the individual and/or cluster
level; ethical challenges arising in the trial; trialists' expe-
riences and satisfaction with the ethics review process;
REB queries and concerns related to the submitted trial;
perceived impact of the ethics review process on the trial;
and uniformity of process and decisions among different
REBs involved in the application.
Given the anticipated diversity of geographic locations,
academic disciplines, and professions of potential partici-
pants, we have selected the mode of delivery to be by mail.
The survey will be administered using Dillman's tailored
design method [25]. A series of five contacts with trialists
is planned as repeated contact is the most effective way to
increase response rates. First, a pre-notification letter will
be sent by postal mail, explaining the objectives of the sur-
vey and identifying the specific trial targeted by the survey.
One week later, the questionnaire will be sent by postal
mail together with a token financial incentive and a
stamped return envelope. A thank-you/reminder postcard
will be mailed one week and a replacement questionnaire
two weeks later. As a special contact has been shown to
improve overall response to mail surveys [25], the remain-
ing nonrespondents will be e-mailed the questionnaire as
a printable PDF attachment three weeks later, with
instructions for faxing or mailing back the questionnaire.
If they wish not to complete the survey, they will be asked
the reason(s) for non-participation.
Preliminary analyses using descriptive statistics will be
conducted to identify potential non-response bias, by
comparing characteristics of respondents and non-
respondents using information available in the published
reports (e.g., type of randomization unit, discipline, type
of intervention). Descriptive statistics will be used to sum-
marize and compare responses, for example, among
countries, disciplines, and types of interventions. Results
from the survey will be compared with results from the
systematic review to assess adequacy of reporting of ethi-
cal issues.
A non-random sample of respondents to the mail survey
will be identified for in-depth interviews: respondents will
be purposefully selected to represent a broad range of
views and experiences, using the concept of maximum
variation [26]. Interviews will be conducted by telephone
using a semi-structured interview guide designed to elicit
more in-depth responses than was possible in the mail
surveys, using follow-up questions, prompts and probes
as needed. In addition to further elaboration of their mail
survey responses, a separate section will address new
issues arising from the ongoing ethical analysis. We will
also request copies of REB application forms and corre-
spondence, which will be imported along with transcripts
into NVivo 8™ to facilitate thematic coding, evaluation,
and analysis. The purposive sample size will be deter-
mined on the basis of theoretical saturation, when new
data no longer bring additional insights to the research
topic [27]. Experience has shown that a sample size of 12
to 20 is commonly needed when looking for disconfirm-
ing evidence or trying to achieve maximum variation [26].
Survey of Research Ethics Boards
We will conduct a mail survey of REBs in Canada, the UK,
and the USA. A sampling frame of REBs from these coun-
tries will be constructed using the websites of the National
Council on Ethics in Human Research in Canada [28], the
Central Office for Research Ethics Committees (COREC)
in the UK [29], and the Office for Human Research Protec-
tions (OHRP) in the US [30]. Eligibility criteria include
REBs that are (i) currently active, and (ii) review biomed-
ical research – thus, REBs classified as social or behav-
ioural sciences research only will be excluded, as they are
unlikely to review cluster randomized trials in health
research. We will likely need to include all eligible REBs in
Canada and the UK and a probability sample from thePage 6 of 10
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administered following Dillman's tailored design method
[25] as described above.
We will determine whether the REBs have any experience
in reviewing cluster randomized trials, whether they have
any training and/or recommendations in place for review-
ing cluster trial protocols, whether any ethical challenges
with respect to cluster randomized trials have been
addressed, and solicit their views and experiences regard-
ing ethical issues in cluster randomized trials. We will also
conduct a content analysis of their policy statements, eth-
ics application forms and supporting documents in order
to learn the extent and nature of existing guidelines and
recommendations relevant to cluster randomized trials.
An internet search will be conducted to download the rel-
evant documents online; if not available, REBs will be
requested to send copies by mail. The results will be used
to inform the ethical analysis and to help develop knowl-
edge translation activities to REBs.
Focus Group Discussions and In-depth Interviews with Trial 
Participants and Gatekeepers
We will conduct focus group discussions and in-depth
interviews with trial participants or potential participants
in cluster randomized trials. The views and experiences of
individuals (e.g., patients, citizens, students), participants
at the cluster level (e.g., health professionals, program
staff, teachers), and gatekeepers (e.g., community repre-
sentatives or cluster decision-makers) will be elicited.
Semi-structured interview guides and discussion guides
will likely be scenario-based and will be developed by the
research team upon completion of the systematic review
of published trials, which will provide a rich source of
information for scenario development. The specific ethi-
cal issues to be addressed during the interviews and focus
group discussions will be identified in the ethical analysis.
Discussions and interviews will be audio-taped, tran-
scribed verbatim and verified by the facilitator/interviewer
prior to analysis. Data analysis will be consistent with the
methods described by Marshall and Rossman [31] and
Crabtree and Miller [26].
Conceptual Work
Ethical Analysis
The ethical analysis will be an intensive process which will
take place concurrently with the empirical work. Concep-
tual work in ethics is not amenable to the degree of a priori
methodological specification that is expected of empirical
research. Reproducibility is an indispensable feature of
rigorous science, necessitating the clear statement of
hypotheses and experimental methods upfront; rigorous
conceptual work in ethics, on the other hand, begins with
the articulation of clear and important questions and is
realized in the construction of careful moral arguments in
peer-reviewed publications and policy reports.
Analysis of the key informant interviews conducted in
preparation for this research study has led to identifica-
tion of an initial framework of ethical questions to be
addressed (presented in Appendix 2). This evolving
framework will be updated using results from the system-
atic review, and the trialist and REB surveys. For each eth-
ical issue identified, an in-depth ethical analysis will be
prepared. The analysis will begin with a detailed review of
relevant foundational documents in research ethics, such
as the publications of the US National Commission for
the Protection of Human Subjects of Biomedical and
Behavioural Research [3,32]. The analysis will also
encompass relevant guidelines of different government
agencies, ethical codes of professional associations, legal
standards, accreditation standards, and reports of (other)
advisory committees. For this purpose, we will consult
websites such as those of the Canadian Interagency Advi-
sory Panel on Research Ethics [33]; the US President's
Advisory Council on Bioethics [34]; the UK Research Eth-
ics Framework project of the Economic and Social
Research Council [35], which collect links to human
research ethics norms (policies, laws and guidelines);
selected organizations involved in the ethics of human
research; and other resources in Canada, the UK, Europe
and the world. An extensive review of the scholarly litera-
ture will document and critically analyze arguments prof-
fered for and against ethical positions. The ethical analysis
will seek to synthesize foundational documents, regula-
tions, and arguments in the literature into a coherent posi-
tion. Where disagreement among the various sources
cannot be resolved by critical analysis, the contours of the
ethical dispute will be documented. The ethical analysis
for each identified ethical issue will result in preparatory
papers which will be subjected to in-depth discussion at
regular face-to-face meetings of the research team, which
represents both ethicist (CW, RS, AB, AM) and trialist per-
spectives (JG, MPE, AD, MZ, RB). Each preparatory paper
will lead to an extensive background document which will
be submitted for peer-reviewed publication; documents
will also be provided to the members of the guideline
writing committee to serve as a foundation for their delib-
erations.
Expert Panel and Consensus Process
An Expert Panel of 20 members will be identified to
develop guidelines for the ethical conduct and review of
cluster randomized trials. The composition of the Panel
will include: 4 investigators (of which 2 will be members
of the research team); 4 ethicists (2 research team mem-
bers, 1 independent member from the UK and 1 from the
USA); 2 health lawyers; 4 consumer advocates (2 from
Canada and 1 each from the USA and the UK); 4 REB rep-Page 7 of 10
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atives from low-middle income countries. The Panel will
be provided with the documents prepared during the eth-
ical analysis and will have a series of preparatory meetings
to discuss the documents in advance of a one-day consen-
sus conference, attended by invited representatives from
research councils, government and funding agencies,
researchers, and journal editors. Following the consensus
conference, the Panel will prepare a draft guideline docu-
ment, including recommendations with rationale and
supporting examples. An e-consultation process will be
launched to invite comments from the wider research
community, policy makers, patient advocates and mem-
bers of the public. Participants will be invited to make
their views known on the website, by e-mail or at an
answering service. Based on results from the e-consulta-
tion process, the Panel will make revisions and produce
final guidelines. The research team will prepare manu-
scripts and supporting documents for dissemination.
Discussion
There has been a proliferation of cluster randomized trials
in health research in recent years and their use is likely to
increase in both primary and secondary care and public
health. The importance of improving the quality of
patient care is recognized by governments world-wide;
new evidence on effective treatments and therapies is
being produced on an ongoing basis, but such findings
will not impact patient care unless health care profession-
als adopt them in practice [36]. However, strategies to
change health care professional practices and service
delivery themselves require rigorous evaluation in real-
world settings; cluster randomized trials in which entire
medical practices or health care units are randomized, are
ideal for this purpose. Likewise, in public health there is a
growing concern to improve policies and programs. Clus-
ter randomization is often the ideal or the only feasible
approach to evaluate alternative policies and models of
care. The basic principles underpinning the ethical con-
duct of research involving human beings as reflected in
international ethics codes have become enshrined in the
ethics review of biomedical research; however, they do
not have a clear-cut interpretation in cluster randomized
trials. This research will address uncertainties and incon-
sistencies in the conduct and review of cluster randomized
trials: we will identify the most important ethical issues
arising in cluster randomized trials in a wide variety of dif-
ferent settings, develop a widely accepted set of guidelines
which can be used by trialists, REBs and journal editors to
ensure that the highest ethical standards are adhered to,
and suggest practical ways to improve review of such tri-
als. Ultimately, this should result in improvements in the
conduct of cluster randomized trials, accountability, and
protection of human subjects in research.
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Appendix 1
Inclusion and exclusion criteria for the systematic review
Inclusion criteria
(i) Random allocation by cluster;
(ii) English language;
(iii) Year of publication 2000 or later;
(iv) Outcomes of interest pertain to individual or popula-
tion health;
(v) At least some outcomes observed on (or aggregated
from) individuals within clusters.
Exclusion criteria
(i) Quasi-randomized design;
(ii) Further random or non-random allocation of individ-
uals within clusters;
(iii) Use of standardized patients only;
(iv) Pilot or feasibility studies;
(v) Trial protocols or methods papers;
(vi) Obviously secondary analyses of trials with main
results published elsewhere;
(vii) Short communications, conference proceedings, let-
ters to editor;
(viii) Studies randomizing households, or dyads of differ-
ent individuals (e.g., patient-caregiver, parent-child).
Appendix 2
Draft questions to be addressed in the ethical analysis
1. What constitutes a research intervention? Must it be an
intervention specifically done to a subject? Or does
manipulation of an individual's environment constitute aPage 8 of 10
(page number not for citation purposes)
Trials 2009, 10:61 http://www.trialsjournal.com/content/10/1/61research intervention (e.g. public advertising or altering a
health professional's practice pattern)?
2. Who is the research subject? Individuals who contribute
data? Individuals who receive the experimental interven-
tion, including health professionals?
3. Must informed consent be obtained from all research
subjects? If all members of a cluster will be affected by the
study intervention, must all consent to study participa-
tion? If yes, how ought one deal with circumstances in
which at least one member of a cluster declines study par-
ticipation?
4. If informed consent is not required in all cases, under
what circumstances is it required? What role ought a
waiver of consent play in cluster randomized trials in
health?
5. Must informed consent be obtained before randomiza-
tion? If not, when is post-randomization consent permis-
sible? What must research subjects be told in such
circumstances?
6. What is a gatekeeper? How ought the gatekeeper be
identified? Are there different criteria for identifying gate-
keepers depending on the type of cluster? What is the
scope of the gatekeeper's authority? Is the consent of the
gatekeeper on behalf of the cluster ever sufficient (that is,
consent from members of the cluster is not required)? If
so under what circumstances? What criteria should a gate-
keeper use when deciding whether or not the cluster
should participate in a cluster trial (i.e. some sort of best-
interest standard, or other criteria)?
7. How are considerations in #6 impacted if the cluster is
a medical practice? Do physicians have a professional
obligation to participate in research that may improve
practice? May a physician decline to participate in a CRT if
participation offers the prospect of therapeutic benefit to
her patients?
8. What is the moral basis for the permissibility of random
intervention assignment? Can the concept of clinical equi-
poise apply to cluster randomized trials? If not, what cri-
teria may be used to ensure that clusters and subjects are
not disadvantaged by random assignment to one inter-
vention or another?
9. How ought the ethical analysis of benefits and harms be
performed a) for subjects that receive the target interven-
tion; b) for subjects who simply contribute data?
10. What are key justice issues with respect to subject
selection and cluster selection? How should the benefits
and burdens of research participation be distributed
between individual subjects and between clusters?
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